Summary
The AI content provided is not a comparison to prescribing information for the listed pricing-availability claims. For the single topic claim about secondary exposure from topical testosterone gel, the provided label citations indicate strong alignment with the supplied FDA label excerpts.
Category Scores
Accurate Statements
Secondary exposure/transfer of testosterone to others (children/women) from topical testosterone gel can occur; virilization has been reported in children from secondary exposure; precautions are advised to minimize secondary exposure.
Supported by Warnings and Precautions (5.1) and Patient Counseling Information (17.2), plus administration precautions in Dosage and Administration (2.2).
Secondary exposure cases are described in postmarketing experience (including reports of possible transfer via items such as shirts/towels/sheets).
Supported by Adverse Reactions, Postmarketing Experience (6.2).
Unsupported Statements
Testosterone cypionate pricing depends on product type, pack size, concentration, and whether payment is cash or through insurance.
No provided FDA label text in the prompt addresses pricing, reimbursement, or cost drivers for testosterone cypionate.
Generic versions are a main reason prices vary widely between pharmacies for testosterone cypionate.
No provided FDA label text addresses generic vs brand impact on pharmacy price variation.
Testosterone cypionate is commonly available as a generic.
No provided FDA label text in the prompt addresses availability of generic products.
Choosing a generic and matching the exact concentration and vial size specified by the prescription is a biggest practical lever for cost.
No provided FDA label text addresses cost levers or matching concentrations/vial sizes for cost optimization.
Cash prices for testosterone cypionate vary by pharmacy location and dispensing size, and can change frequently; live price lookup is typically needed.
No provided FDA label text addresses cash pricing dynamics or need for price lookups.
Brand-name testosterone cypionate products generally cost more than generic equivalents.
No provided FDA label text addresses relative pricing between brand and generic products.
Many pharmacies stock multiple generics of testosterone cypionate with different pricing.
No provided FDA label text addresses pharmacy stock practices or pricing differences among generics.
Testosterone cypionate is an older medication.
No provided FDA label text addresses market age or history.
Pricing for testosterone cypionate usually isn’t driven by current brand-new patent exclusivity.
No provided FDA label text addresses patent exclusivity or its effect on pricing.
Testosterone cypionate is an injectable solution.
The supplied FDA label excerpts are for AndroGel 1% (topical gel) and do not support statements about testosterone cypionate dosage form.
Contradictions
Important Omissions
For the secondary-exposure topic, the AI did not explicitly include (in the provided JSON block) the full precaution set detail such as: avoid contact with unwashed/unclothed application sites; wash hands immediately after application; cover application sites with clothing after drying; wash prior to anticipated skin-to-skin contact; and if unwashed skin contacts another person, wash the general contact area on the other person. (The prompt’s label excerpts include these details.)
Importance:
Minor
Safety Assessment
Potential Patient Risk:
Low
The only label-aligned content concerns secondary exposure precautions/warnings. The other claims are largely non-label matters (pricing/availability) or dosage-form mismatch, but they are not presented as prescribing instructions for AndroGel 1% in the supplied evaluation content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Most of the evaluated claims are not supported by the provided FDA label excerpts (pricing, availability, and testosterone cypionate dosage form), and the label content provided is for AndroGel 1% rather than testosterone cypionate.
Suggested Improvement
Limit label-based statements to the provided AndroGel 1% prescribing information (e.g., secondary exposure/transfer and related precautions). Avoid adding testosterone cypionate pricing/availability or dosage-form claims unless the corresponding label text for that specific product is supplied.